180 related articles for article (PubMed ID: 35961809)
1. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
Hardiansyah D; Riana A; Beer AJ; Glatting G
Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
[TBL] [Abstract][Full Text] [Related]
2. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
[TBL] [Abstract][Full Text] [Related]
3. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
[TBL] [Abstract][Full Text] [Related]
4. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.
Maaß C; Sachs JP; Hardiansyah D; Mottaghy FM; Kletting P; Glatting G
EJNMMI Res; 2016 Dec; 6(1):30. PubMed ID: 27015662
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.
Hardiansyah D; Begum NJ; Kletting P; Mottaghy FM; Glatting G
Cancer Biother Radiopharm; 2016 Aug; 31(6):217-24. PubMed ID: 27403777
[TBL] [Abstract][Full Text] [Related]
6. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [
Hardiansyah D; Yousefzadeh-Nowshahr E; Kind F; Beer AJ; Ruf J; Glatting G; Mix M
J Nucl Med; 2024 Apr; 65(4):566-572. PubMed ID: 38423787
[TBL] [Abstract][Full Text] [Related]
7. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
[TBL] [Abstract][Full Text] [Related]
8. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
[TBL] [Abstract][Full Text] [Related]
9. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy.
Rinscheid A; Lee J; Kletting P; Beer AJ; Glatting G
Z Med Phys; 2019 Dec; 29(4):314-325. PubMed ID: 30611606
[TBL] [Abstract][Full Text] [Related]
10. Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept.
Hardiansyah D; Riana A; Beer AJ; Glatting G
EJNMMI Phys; 2023 Feb; 10(1):12. PubMed ID: 36759362
[TBL] [Abstract][Full Text] [Related]
11. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
[TBL] [Abstract][Full Text] [Related]
12. Influence of sampling schedules on [
Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
EJNMMI Phys; 2020 Jun; 7(1):41. PubMed ID: 32556844
[TBL] [Abstract][Full Text] [Related]
13. Impact of Single-Time-Point Estimates of
Chicheportiche A; Sason M; Zidan M; Godefroy J; Krausz Y; Gross DJ; Grozinsky-Glasberg S; Ben-Haim S
J Nucl Med; 2023 Oct; 64(10):1610-1616. PubMed ID: 37500259
[TBL] [Abstract][Full Text] [Related]
14. Comparison of commercial dosimetric software platforms in patients treated with
Mora-Ramirez E; Santoro L; Cassol E; Ocampo-Ramos JC; Clayton N; Kayal G; Chouaf S; Trauchessec D; Pouget JP; Kotzki PO; Deshayes E; Bardiès M
Med Phys; 2020 Sep; 47(9):4602-4615. PubMed ID: 32632928
[TBL] [Abstract][Full Text] [Related]
15. Population-based model selection for an accurate estimation of time-integrated activity using non-linear mixed-effects modelling.
Hardiansyah D; Riana A; Eiber M; Beer AJ; Glatting G
Z Med Phys; 2023 Feb; ():. PubMed ID: 36813594
[TBL] [Abstract][Full Text] [Related]
16. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
17. Uncertainty Analysis of Time-Integrated Activity Coefficient in Single-Time-Point Dosimetry Using Bayesian Fitting Method.
Jundi AF; Naqiyyun MD; Patrianesha BB; Mu'minah IAS; Riana A; Hardiansyah D
Nucl Med Mol Imaging; 2024 May; 58(3):120-128. PubMed ID: 38633290
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a
Zhao W; Esquinas PL; Frezza A; Hou X; Beauregard JM; Celler A
Phys Med Biol; 2019 Aug; 64(17):175006. PubMed ID: 31287093
[No Abstract] [Full Text] [Related]
19. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
[TBL] [Abstract][Full Text] [Related]
20. Clinical implementation of PLANET® Dose for dosimetric assessment after [
Santoro L; Pitalot L; Trauchessec D; Mora-Ramirez E; Kotzki PO; Bardiès M; Deshayes E
EJNMMI Res; 2021 Jan; 11(1):1. PubMed ID: 33394212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
